Haleon plc (HLN)vsViatris Inc (VTRS)
HLN
Haleon plc
$9.11
-2.04%
HEALTHCARE · Cap: $40.43B
VTRS
Viatris Inc
$17.17
-1.27%
HEALTHCARE · Cap: $20.25B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 32% more annual revenue ($14.56B vs $11.03B). HLN leads profitability with a 15.1% profit margin vs -2.0%. VTRS appears more attractively valued with a PEG of 0.15. HLN earns a higher WallStSmart Score of 63/100 (C+).
HLN
Buy63
out of 100
Grade: C+
VTRS
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-22.4%
Fair Value
$9.12
Current Price
$9.11
$0.01 premium
Margin of Safety
+33.6%
Fair Value
$24.30
Current Price
$17.17
$7.13 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 92.0% YoY
Reasonable price relative to book value
Strong operational efficiency at 23.2%
Generating 1.3B in free cash flow
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
0.6% revenue growth
ROE of -2.0% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : HLN
The strongest argument for HLN centers on EPS Growth, Price/Book, Operating Margin. Profitability is solid with margins at 15.1% and operating margin at 23.2%.
Bull Case : VTRS
The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.15 suggests the stock is reasonably priced for its growth.
Bear Case : HLN
The primary concerns for HLN are PEG Ratio, Revenue Growth.
Bear Case : VTRS
The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
HLN profiles as a value stock while VTRS is a turnaround play — different risk/reward profiles.
VTRS carries more volatility with a beta of 0.87 — expect wider price swings.
VTRS is growing revenue faster at 8.1% — sustainability is the question.
HLN generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
HLN scores higher overall (63/100 vs 48/100), backed by strong 15.1% margins. VTRS offers better value entry with a 33.6% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a prominent global player in the consumer health sector, dedicated to providing innovative health solutions through its diverse portfolio, which includes renowned brands like Sensodyne, Panadol, and Voltaren. Established as a spin-off from GlaxoSmithKline, the company leverages its strong brand equity to cater to critical health segments such as oral care, pain relief, and dietary supplements. Committed to sustainability and consumer-centric innovation, Haleon is strategically positioned to enhance health outcomes worldwide while pursuing growth and generating value for its shareholders through targeted investments and continuous product development.
Visit Website →Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?